Camostat Mesylate for Protein-losing Enteropathy After Fontan Operation

Summary

This study is phase 2 open-label, single-arm, multi-center clinical trial to evaluate the efficacy and safety of Camostat mesylate in patients with Protein-losing enteropathy after Fontan operation.

Timeline

Start

2022-10-03

Primary completion

2024-07-12

Completion

2024-10-08

Publications

• Park WY, Kim GB, Lee SY, Baek JS, Kim SJ, Jung J, Hyun MC, Lim YT, Lee H, Ko H, Lee J. Phase 2 Open-label, Single-arm, Multi-center Clinical Trial to Evaluate the Efficacy and Safety of Camostat Mesylate in Patients with Protein-losing Enteropathy After Fontan Operation. Pediatr Cardiol. 2026 Mar;47(3):932-940. doi: 10.1007/s00246-025-03859-9. Epub 2025 Apr 14.

Drugs

Indications